NXI Therapeutics AG
|Category:||Emerging Biotech Company|
|Date:||April 25, 2023|
|Speaker:||Ruben Herrendorff, CEO|
NXI Therapeutics is a spin-off from the Biozentrum, University of Basel, Switzerland and is committed to creating tomorrows safe immunotherapies by leveraging a novel targeted approach in T cell immunology. NXI Therapeutics is pioneering the development of selective immunomodulators that target the Coronin 1 pathway, which regulates those T cell immune responses that play a key role in graft rejection and autoimmunity, while leaving the protective immune responses intact.